[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Altimmune Inc (ALT)

Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 560,085
  • Shares Outstanding, K 194,474
  • Annual Sales, $ 40 K
  • Annual Income, $ -88,090 K
  • EBIT $ -94 M
  • EBITDA $ -96 M
  • 60-Month Beta 0.27
  • Price/Sales 13,897.78
  • Price/Cash Flow N/A
  • Price/Book 1.34

Options Overview Details

View History
  • Implied Volatility 78.02% (+0.55%)
  • Historical Volatility 41.22%
  • IV Percentile 22%
  • IV Rank 7.76%
  • IV High 444.78% on 12/29/25
  • IV Low 47.16% on 08/20/25
  • Expected Move (DTE 7) 0.20 (6.70%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 7,504
  • Volume Avg (30-Day) 3,896
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 179,447
  • Open Int (30-Day) 169,675
  • Expected Range 2.72 to 3.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 4
  • High Estimate $-0.11
  • Low Estimate $-0.21
  • Prior Year $-0.21
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.75 +6.73%
on 07/23/26
3.31 -11.33%
on 07/28/26
unch (+0.17%)
since 07/14/26
3-Month
2.57 +14.19%
on 06/11/26
3.40 -13.68%
on 07/01/26
+0.01 (+0.51%)
since 05/14/26
52-Week
2.56 +14.65%
on 05/01/26
6.44 -54.42%
on 01/23/26
-0.75 (-20.24%)
since 08/14/25

Most Recent Stories

More News
Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million...

ALT : 2.95 (+2.43%)
Altimmune Reports Another Quarter Where the Path to Profitability Remains Theoretical

Barchart Research What to Expect from ALT Earnings ALT Generated August 11, 2026 Current Price $3.00 EPS Estimate $$-0.15 Consensus Rating Strong Buy Average Move 11.06% Altimmune Reports Another Quarter...

ALT : 2.95 (+2.43%)
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced...

ALT : 2.95 (+2.43%)
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes  Initiation marks advancement of Altimmune's lead program into late-stage...

ALT : 2.95 (+2.43%)
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial  Important secondary endpoints were also met,...

ALT : 2.95 (+2.43%)
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial

Altimmune (NASDAQ:ALT) executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis,...

ALT : 2.95 (+2.43%)
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors PERFORMA Phase 3 trial...

ALT : 2.95 (+2.43%)
Altimmune to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced...

ALT : 2.95 (+2.43%)
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

Concurrent improvement across key non-invasive tests underscores convergence of  pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate...

ALT : 2.95 (+2.43%)
Altimmune Q1 Earnings Call Highlights

Altimmune (NASDAQ:ALT) said it has strengthened its balance sheet and is preparing to begin a global Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, in the second...

ALT : 2.95 (+2.43%)

Business Summary

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 3.07
2nd Resistance Point 3.01
1st Resistance Point 2.95
Last Price 2.95
1st Support Level 2.83
2nd Support Level 2.77
3rd Support Level 2.71

See More

52-Week High 6.44
Fibonacci 61.8% 4.96
Fibonacci 50% 4.50
Fibonacci 38.2% 4.04
Last Price 2.95
52-Week Low 2.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.